News

In this interview, Rashieda Gluck, Senior VP, Global Clinical Operations, at Aurinia Pharmaceuticals, will discuss how patient centricity techniques are benefiting smaller biopharmaceutical companies.

The instructions of a legendary 19th recipe for jugged hare began: "First catch your hare".

EMA drafted a plan for closer engagement with regulatory science in the next ten years, and it is looking for comments on its approach.

From average merit increases from individual countries, to incentives per position, to retention bonuses and much more, a recent BDO report offers a robust look at an industry that has quickly eclipsed its “small company mentality” roots.

Right now, we only seek “perfect patients” for our trials, rendering many drugs potentially less safe or effective for those in demographics the study was not designed for.

Click the title above to open the Applied Clinical Trials January/February 2019 issue in an interactive PDF format.

FDA prioritizes to maintain, and continue to improve, the efficient and effective drug development and review system the agency has established in recent years.

An increase in use of EHR systems at clinical investigative sites adds more expectations for clinical trial sponsors to comply by regulatory requirements.

Case study demonstrates how one global mid-sized sponsor is testing the RBM waters.

Using data analytics to introduce parallel processes to optimize and accelerate clinical trials.

RBM is an emerging area which gives endless opportunities to explore, transform, and evolve.

DIA Europe proves to have excellent timing to learn more about the latest developments in drug development, the current status of Brexit, the plans of the National regulators and EMA, on-going discussions on pan-European HTA, and the trends for 2019.

2018 has been an exciting year in the clinical trials industry, as we have seen many changes in novel concepts, and the evolution of some concepts to the point where initiatives and pilots are crystalizing into common practice.

Using data analytics to introduce parallel processes to optimize and accelerate clinical trials.

Updated employee announcements, business news, awards, and recognition in the industry today.

In this Q&A, Helen Matthews, Jessica Morris, and Bruce Hellman offer their perspectives on the priorities, opportunities, and challenges of patient centricity in real-world evidence collection.

Risk-based approaches to monitoring (RBM) have become widely accepted in the clinical trials industry.